黑色素瘤免疫治疗停止后的生存:系统综述与荟萃分析
该系统综述与荟萃分析纳入20项研究共1832例晚期黑色素瘤患者,评估停用免疫检查点抑制剂(ICI)后的应答持久性。汇总停药后1年和3年无进展生存(PFS)率分别为86%(95%CI 80%-91%)和71%(95%CI 64%-77%),1年和3年总生存(OS)率分别为96%(95%CI 91%-99%)和86%(95%CI 79%-92%)。主动停药者1年PFS率(91%)显著高于因毒性停药者(79%),治疗时间较长与较高PFS率相关;治疗至少2年的患者是停药的理想候选,至少1年后可考虑停药。
要点
- 晚期黑色素瘤停用ICI后多数患者无复发,1年和3年PFS率分别为86%和71%。
- 主动停药者1年PFS率(91%)显著高于因不良事件停药者(79%)。
- 治疗至少2年的患者是停药的理想候选,至少1年后可考虑停药。
核心结论
- 多数晚期黑色素瘤患者停用ICI后保持无复发,治疗至少2年者为停药理想候选,至少1年后可考虑停药。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE/PubMed、Embase和Cochrane Library,纳入20项研究共1832例晚期黑色素瘤患者,采用随机效应模型汇总停药后1至3年PFS和OS率。
主要发现
- 停药后汇总1年和3年PFS率分别为86%(95%CI 80%-91%)和71%(95%CI 64%-77%)。
- 主动停药者1年PFS率显著高于毒性相关停药者(91% vs. 79%)。
- 较长ICI治疗时间与较高PFS率相关。
- 停药后1年和3年OS率分别为96%(95%CI 91%-99%)和86%(95%CI 79%-92%)。
关键数值与推荐
- 治疗至少2年的患者是停药的理想候选。
- 至少1年ICI治疗后可能考虑停药。
临床怎么用
- 对晚期黑色素瘤患者,ICI治疗至少2年者可考虑主动停药,至少1年后可评估停药可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune-checkpoint inhibitor (ICI) therapy elicits durable responses in a subset of patients with advanced melanoma. However, the appropriate timing for treatment cessation remains an unresolved issue. Moreover, some patients are required to discontinue therapy due to the occurrence of severe adverse events. Upon treatment cessation, a subset of patients maintains a durable response, while some patients relapse and require rechallenge with ICI. Criteria for a safe stop of ICI have not been established. OBJECTIVES: The aim of this systematic review and meta-analysis was to evaluate the durability of response in melanoma patients who discontinued ICI therapy. Furthermore, the outcome of patients who electively stopped therapy was compared to that of patients who discontinued therapy due to adverse events. METHODS: MEDLINE/PubMed, Embase and the Cochrane Library were searched for studies reporting outcomes after ICI discontinuation in patients with advanced melanoma. Pooled 1- to 3-year progression-free survival (PFS) and overall survival (OS) rates were estimated using random-effects models. The impact of the reason for treatment discontinuation, therapy regime and treatment duration on relapse-free survival was evaluated. RESULTS: Twenty studies including 1832 patients were analysed. The pooled 1- and 3-year PFS rates after therapy stop were 86% (95% CI 80%-91%) and 71% (95% CI 64%-77%). A significantly higher 1-year PFS rate was observed in patients who electively discontinued treatment in contrast to toxicity-related therapy cessation (91% vs. 79%). Longer ICI treatment was associated with a higher PFS rate. 1- and 3-year OS rates post ICI treatment discontinuation were 96% (95% CI 91%-99%) and 86% (95% CI 79%-92%). CONCLUSIONS: Most patients remained relapse-free after ICI treatment. Patients with a treatment duration of at least 2 years are ideal candidates for treatment cessation, while treatment discontinuation may be considered after at least 1 year of ICI. PROSPERO number: CRD42024543781.
引用
- Mayer KE, Warburton L, Zaremba A, et al. Survival after cessation of immunotherapies in melanoma: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2025. PMID: 40181695. doi:10.1111/jdv.20672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。